{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.67","upperLimit":"19.8","value":"8.21"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"}],"units":"Participants"}],"title":"Tazemetostat"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"8.10","upperLimit":"22.8","value":"15.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"}],"units":"Participants"}],"title":"EPZ-6930"}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"}],"units":"Participants"}],"description":"Blood samples were collected at specified timepoints. T1/2 was assessed using non-compartmental data analysis method.","dispersionType":"Full Range","groups":[{"description":"Participants received a single oral dose of 400 mg tazemetostat on Cycle 1 Day 1, BID dose of tazemetostat 400 mg on Days 3 to 14 and single dose of tazemetostat 400 mg on Day 15. From Days 21 to 35, they received a 400 mg BID dose of tazemetostat. On Cycle 1 Day 36, they received a single dose of 400 mg tazemetostat. Participants continued to receive tazemetostat treatment at the recommended therapeutic dose (oral 800 mg tazemetostat BID), from Day 40 (Cycle 2 Day 1) for each subsequent cycle of 28-day duration until Investigator assessed clinical progression per standard practice, unacceptable treatment related toxicity/withdrawal; survival follow-up (until death/study closure).","id":"OG000","title":"Part 1: Tazemetostat"}],"paramType":"MEDIAN","populationDescription":"The PK population included all participants who had sufficient PK concentration data to calculate steady-state PK parameters in Part 1 and did not have any major protocol deviation that was deemed to greatly alter the steady-state exposure to tazemetostat or itraconazole. Only data from the participants analyzed were reported.","reportingStatus":"POSTED","timeFrame":"Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, 12, 36, and 72 hours post-dose on Cycle 1 Day 15","title":"Part 1: Apparent Terminal Elimination Half-Life (t1/2) of Tazemetostat and EPZ-6930 After Tazemetostat Alone at Steady-State","type":"SECONDARY","unitOfMeasure":"hour"}